JP2014506890A5 - - Google Patents

Download PDF

Info

Publication number
JP2014506890A5
JP2014506890A5 JP2013554520A JP2013554520A JP2014506890A5 JP 2014506890 A5 JP2014506890 A5 JP 2014506890A5 JP 2013554520 A JP2013554520 A JP 2013554520A JP 2013554520 A JP2013554520 A JP 2013554520A JP 2014506890 A5 JP2014506890 A5 JP 2014506890A5
Authority
JP
Japan
Prior art keywords
hydroxy
use according
methylbutyrate
disease
mechirubuchira
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013554520A
Other languages
English (en)
Japanese (ja)
Other versions
JP6034309B2 (ja
JP2014506890A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/024817 external-priority patent/WO2012112419A1/en
Publication of JP2014506890A publication Critical patent/JP2014506890A/ja
Publication of JP2014506890A5 publication Critical patent/JP2014506890A5/ja
Application granted granted Critical
Publication of JP6034309B2 publication Critical patent/JP6034309B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013554520A 2011-02-17 2012-02-13 β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法 Expired - Fee Related JP6034309B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161443762P 2011-02-17 2011-02-17
US61/443,762 2011-02-17
PCT/US2012/024817 WO2012112419A1 (en) 2011-02-17 2012-02-13 Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016209276A Division JP6340394B2 (ja) 2011-02-17 2016-10-26 β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法

Publications (3)

Publication Number Publication Date
JP2014506890A JP2014506890A (ja) 2014-03-20
JP2014506890A5 true JP2014506890A5 (cg-RX-API-DMAC7.html) 2015-03-26
JP6034309B2 JP6034309B2 (ja) 2016-11-30

Family

ID=45757211

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013554520A Expired - Fee Related JP6034309B2 (ja) 2011-02-17 2012-02-13 β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法
JP2016209276A Expired - Fee Related JP6340394B2 (ja) 2011-02-17 2016-10-26 β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016209276A Expired - Fee Related JP6340394B2 (ja) 2011-02-17 2016-10-26 β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法

Country Status (12)

Country Link
US (1) US9326956B2 (cg-RX-API-DMAC7.html)
EP (1) EP2675298A1 (cg-RX-API-DMAC7.html)
JP (2) JP6034309B2 (cg-RX-API-DMAC7.html)
CN (1) CN103347406B (cg-RX-API-DMAC7.html)
AR (1) AR085297A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013020643A2 (cg-RX-API-DMAC7.html)
CA (1) CA2825734C (cg-RX-API-DMAC7.html)
MX (1) MX348708B (cg-RX-API-DMAC7.html)
PH (1) PH12013501671A1 (cg-RX-API-DMAC7.html)
SG (1) SG192813A1 (cg-RX-API-DMAC7.html)
TW (1) TWI565420B (cg-RX-API-DMAC7.html)
WO (1) WO2012112419A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG182812A1 (en) 2010-01-29 2012-09-27 Abbott Lab Nutritional emulsions comprising calcium hmb
WO2011094548A1 (en) 2010-01-29 2011-08-04 Abbott Laboratories Aseptically packaged nutritional liquids comprising hmb
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣hmb及可溶性蛋白質之實質上透明營養液
US9326956B2 (en) 2011-02-17 2016-05-03 Abbott Laboratories Methods for improving brain development and cognitive function using beta-hydroxy-beta methylbutyrate
ES2421187B1 (es) * 2012-02-23 2014-11-26 Abbott Laboratories Metodo para mejorar el desarrollo cerebral y la funcion cognitiva usando beta-hidroxi-beta-metilbutirato
EP2745708A1 (en) * 2012-12-24 2014-06-25 Abbott Laboratories, Inc. Antidepressant effect of ß-hydroxy-ß-methylbutyrate
US20150351438A1 (en) * 2013-01-29 2015-12-10 Otc Nutrition Llc Micronutrient Fortification Delivery
WO2014127112A1 (en) * 2013-02-13 2014-08-21 Baylor College Of Medicine Memory enhancer and actin dynamics
US20160029683A1 (en) * 2013-03-15 2016-02-04 Abbott Laboratories Low calorie infant formula containing beta-hydroxy-beta-methylbutyric acid
WO2015148982A1 (en) 2014-03-27 2015-10-01 Winterfield Roland W Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
WO2017048708A1 (en) * 2015-09-16 2017-03-23 Abbott Laboratories Reduced fat, shelf stable liquid nutritional composition
BR112018009406A8 (pt) * 2015-11-10 2019-02-26 Metabolic Tech Inc ?composição de aditivo de ração, produto de ração, método para prevenir, eliminar e/ou reduzir crescimento microbiano, e, revestimento para um produto de ração animal?
JP7011300B2 (ja) * 2017-12-19 2022-02-10 株式会社島田製薬 HMBCa含有顆粒の製造方法、及びサプリメント

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291525B1 (en) * 1999-09-08 2001-09-18 Iowa State University Research Foundation, Inc. Method for improving a human's perception of his emotional state
US7445807B2 (en) 2002-10-15 2008-11-04 Western Holdings, Llc Agglomerated granular protein-rich nutritional supplement
US20050027005A1 (en) 2003-08-02 2005-02-03 Matthias Boldt Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
PL371081A1 (pl) 2004-11-08 2006-05-15 Sgp & Sons Ab Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt
US20060167075A1 (en) 2005-01-25 2006-07-27 Pearson James P Modulators of FAAH
US20080317886A1 (en) * 2005-11-03 2008-12-25 Sparkman Dennis R Compositions for Preventing and Reducing Delayed Onset Muscle Soreness
ES2548432T3 (es) 2005-12-19 2015-10-16 Abbott Laboratories Uso de beta-hidroxi-beta-metilbutirato para modular el desequilibrio en la producción de citoquinas de tipo 1 y tipo 2
WO2009116546A1 (ja) 2008-03-18 2009-09-24 国立大学法人 岡山大学 興奮性化学伝達調節剤およびそのスクリーニング法
DK2381784T3 (en) 2008-12-09 2018-10-22 Metabolic Tech Inc Nutritional intervention to improve muscle function and strength
JP2009155336A (ja) * 2009-03-31 2009-07-16 Tsujido Chemical Corp 治療剤
TW201117736A (en) 2009-11-17 2011-06-01 Hui-Chiang Lu Compositions for sport supplement
CN101785566A (zh) 2010-01-22 2010-07-28 北京康比特体育科技股份有限公司 一种含有hmb的运动饮料
CN103338658A (zh) 2010-12-22 2013-10-02 雅培制药有限公司 含有β-羟基-β甲基丁酸钙和共轭亚油酸的营养型产品
EP2658535A1 (en) 2010-12-27 2013-11-06 Abbott Laboratories Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate
US9326956B2 (en) 2011-02-17 2016-05-03 Abbott Laboratories Methods for improving brain development and cognitive function using beta-hydroxy-beta methylbutyrate
SG11201405905WA (en) 2012-03-19 2014-11-27 Abbott Lab Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance
MX2015003498A (es) 2012-09-17 2015-06-04 Abbott Lab Composiciones que contienen acido beta-hidroxi-beta-metilbutirico y usos de las mismas.

Similar Documents

Publication Publication Date Title
AU2017291414B2 (en) Anti-N3pGLu amyloid beta peptide antibodies and uses thereof
Poletti et al. Cognitive and affective Theory of Mind in neurodegenerative diseases: neuropsychological, neuroanatomical and neurochemical levels
CL2019000129A1 (es) Compuestos diazaheterobicíclicos sustituidos y su uso.
BR112015014800A2 (pt) derivados da exendina-4 funcionalizada
SG10201903474PA (en) New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs
PH12015500106B1 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
IL232764A (en) Fluoromethyl6,5 - Dihydro - 4 H - [3,1] Oxazines, Pharmaceuticals Containing Them and Their Use in the Preparation of Medicines to Treat Alzheimer's Disease
HK1211483A1 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
JP2014514361A5 (cg-RX-API-DMAC7.html)
JP2014507474A5 (cg-RX-API-DMAC7.html)
JP2014516535A5 (cg-RX-API-DMAC7.html)
HRP20210361T1 (hr) Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja
JP2016524608A5 (cg-RX-API-DMAC7.html)
BR112013005226A2 (pt) "n-fenetiltriazolonaacetamidas substituídas e o seu uso".
Isaac Culture‐bound syndromes in mental health: A discussion paper.
RU2017123243A (ru) Состав, содержащий экстракт кожицы poria cocos, предназначенный для профилактики, облегчения состояния и лечения нейродегенеративных расстройств
BR112013006307A2 (pt) fenilacetamidas e fenilpropanamidas substituídas e o seu uso
Shepherd A play on mental illness
MX2014001940A (es) Producto farmaceutico de aerosol para administracion por inhalacion oral o nasal.
WO2011015646A3 (en) Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
Jung et al. The Factors to Affect The Duration of Exclusive Breast Feeding of The Infant Mothers
Messinger-Rapport et al. Clinical update on nursing home medicine: 2011
Paxton Time for Dementia
PL3085383T3 (pl) Kompozycja farmaceutyczna zawierająca erytropoietynę i ceftriakson oraz jej wykorzystanie w wytwarzania leku do leczenia choroby parkinsona
Saxena et al. Assessment of neuropro-tective potential of Tualang honey in Alzheimer model of rat